A multicentric phase II trial of gemcitabine (Gem), oxaliplatin (Oxa) and vinorelbine (VNB) in untreated stage IIIB and IV non-small cell lung cancer (NSCLC) patients (pts): Preliminary results of GON triplet regimen

J. Tredaniel,C Becht,M. Bekradda,Stéphane Culine,H. de Cremoux,Misset Jl,A Alexandre,François Goldwasser,F. Chomy,E. Ecstein-Fraisse,E. Cvitkovic

A multicentric phase II trial of gemcitabine (Gem), oxaliplatin (Oxa) and vinorelbine (VNB) in untreated stage IIIB and IV non-small cell lung cancer (NSCLC) patients (pts): Preliminary results of GON triplet regimen

2006

J. Tredaniel
C Becht
M. Bekradda
Stéphane Culine
H. de Cremoux
Misset Jl
A Alexandre
François Goldwasser
F. Chomy
E. Ecstein-Fraisse
E. Cvitkovic

17104 Background: Oxa, Gem and VNB are active agents against NSCLC and have shown synergy in combination. VNB plus Gem showed efficacy comparable to platinum combinations with a more favorable toxi...

Keywords:

non-small cell lung cancer (NSCLC)
Regimen
Cancer research
Gemcitabine
Vinorelbine
Oxaliplatin
Oncology
Internal medicine
Medicine
stage iiib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations